Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES

Autor: Chiang, C.E., Schwartz, G.G., Elbez, Y., Szarek, M., Bhatt, D.L., Bittner, V.A., Diaz, R., Erglis, A., Goodman, S.G., Hagstrom, E., Jukema, J.W., Liberopoulos, E., Loy, M., Pordy, R., White, H.D., Simon, T., Steg, P.G., ODYSSEY OUTCOMES Investigators

Publikováno v: Canadian Journal of Cardiology, 38(10), 1542-1549. ELSEVIER SCIENCE INC

Background: After acute coronary syndrome (ACS), patients with a previous myocardial infarction (MI) may be at particularly high risk for major adverse cardiovascular events (MACE) and death. We studied the effects of the PCSK9 inhibitor alirocumab i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9965a1584134d49a3a58b935c4fa014e
https://doi.org/10.1016/j.cjca.2022.05.021

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept

Autor: Ahmad, HA, Baker, JF, Conaghan, P, Emery, P, Huizinga, TWJ, Elbez, Y, Banerjee, S, Østergaard, M

Publikováno v: Arthritis Research and Therapy, 24(1). BMC
Ahmad, H A, Baker, J F, Conaghan, P G, Emery, P, Huizinga, T W J, Elbez, Y, Banerjee, S & Østergaard, M 2022, ' Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis : post hoc analysis of a phase IIIb trial with abatacept ', Arthritis Research and Therapy, vol. 24, no. 1, 47 . https://doi.org/10.1186/s13075-022-02735-8

Background Drug-free remission is a desirable goal in rheumatoid arthritis (RA) for both patients and clinicians. The aim of this post hoc analysis was to investigate whether clinical and magnetic resonance imaging (MRI) variables in patients with ea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3633d111880209ca7525f38394351eb9
https://doi.org/10.1186/s13075-022-02735-8

PE.Di-013 - Les facteurs prédictifs du maintien d’abatacept IV dépendent-ils de la ligne de traitement de la polyarthrite rhumatoïde ? Analyse intermédiaire à 12 mois de l’étude observationnelle et prospective ACTION

Autor: Mariette, X. ⁽¹⁾, Cantagrel, A. ⁽²⁾, Alten, R. ⁽³⁾, Nüßlein, H.G. ⁽⁴⁾, Galeazzi, M. ⁽⁵⁾, Lorenz, H.M. ⁽⁶⁾, Chartier, M. ⁽⁷⁾, Elbez, Y. ⁽⁸⁾, Rauch, C. ⁽⁹⁾, Le Bars, M. ⁽¹⁰⁾

Publikováno v: In Revue du rhumatisme November 2016 83 Supplement 1:A170-A170

PE.Di-011 - L’indice de masse corporelle n’a pas d’impact sur le maintien d’abatacept chez les patients naïfs de biologiques atteints de polyarthrite rhumatoïde avec des facteurs de mauvais pronostic : analyse intermédiaire à 12 mois d’une étude observationnelle

Autor: Mariette, X. ⁽¹⁾, Cantagrel, A. ⁽²⁾, Alten, R. ⁽³⁾, Lorenz, H.M. ⁽⁴⁾, Nüßlein, H.G. ⁽⁵⁾, Galeazzi, M. ⁽⁶⁾, Chartier, M. ⁽⁷⁾, Elbez, Y. ⁽⁸⁾, Rauch, C. ⁽⁹⁾, Le Bars, M. ⁽¹⁰⁾

Publikováno v: In Revue du rhumatisme November 2016 83 Supplement 1:A168-A169